Yes, this drug (ARV-110) represents a 'first in class' and a positive progress report would be great.
The company that is developing the drug will present at the next ASCO meeting. Here is a link to a very recent press release from them:
https://www.globenewswire.com/news-release/2020/05/13/2033092/0/en/arvinas-announces-updated-phase-1-data-demonstrating-clinical-activity-of-protac-protein-degrader-arv-110-in-patients-with-refractory-prostate-cancer.htmlAs mentioned, this trial is a dose escalation study.
Post Edited (Sr Sailor) : 6/9/2020 6:44:09 PM (GMT-6)